Fibrosis due to ergot derivatives. Exposure to risk should be weighed up

Prescrire International

Volumn 11, Issue 62, 2002, Pages 186-189

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; ANTIPARKINSON AGENT; BROMOCRIPTINE; CABERGOLINE; DIHYDROERGOCRISTINE; DIHYDROERGOCRYPTINE; DIHYDROERGOTAMINE; DIHYDROERGOTOXINE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT DERIVATIVE; ERGOTAMINE; LEVODOPA; LISURIDE; METHYLERGOMETRINE; METHYSERGIDE; NICERGOLINE; PERGOLIDE; PRAMIPEXOLE; QUINAGOLIDE; ROPINIROLE; STEROID; VASOACTIVE AGENT;

ABDOMINAL AORTA; ANEMIA; ANURIA; ARTERY COMPRESSION; COGNITIVE DEFECT; CONSTRICTIVE PERICARDITIS; COUGHING; DRUG INDICATION; DRUG WITHDRAWAL; DYSPNEA; ENDOCRINE DISEASE; FIBROSIS; HEART DISEASE; HEART FAILURE; HUMAN; HYDRONEPHROSIS; KIDNEY DISEASE; LEG EDEMA; LEG VEIN; LONG TERM CARE; LUNG DISEASE; LUNG FIBROSIS; MIGRAINE; MITRAL VALVE REGURGITATION; PARESTHESIA; PARKINSON DISEASE; PERICARDIAL DISEASE; PLEURA DISEASE; PLEURA EFFUSION; PLEURA THICKENING; RESPIRATORY FAILURE; RETROPERITONEAL FIBROSIS; REVIEW; SENSORY DYSFUNCTION; THORAX PAIN; URETER STRICTURE; URINARY TRACT DISEASE; VALVULAR HEART DISEASE; VEIN OCCLUSION; ARTICLE; CHEMICALLY INDUCED DISORDER; FRANCE; RISK ASSESSMENT; RISK FACTOR;

DIHYDROERGOTAMINE; ERGOTAMINE; FIBROSIS; FRANCE; HUMANS; METHYSERGIDE; RISK ASSESSMENT; RISK FACTORS;

EID: 0036884899     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. French datasheet compendium "Dictionnaire Vidal" Vidal, Paris 2002.
2. Graham JR "Methysergide for prevention of headache. Experience in five hundred patients over three years" N Engl J Med 1964, 270 (2): 67-72.
3. Graham JR et al. "Fibrotic disorders associated with methysergide therapy for headache" N Engl J Med 1966; 274 (7): 359-368.
4. Bucci JA and Manoharan A "Methysergide-induced retroperitoneal fibrosis: successful outcome and two new laboratory features" Mayo Clin Proc 1997; 72: 1148-1150.
5. Weiss JM and Hinman F "Reversible retroperitoneal fibrosis with ureteral obstruction associated with ingestion of sansert" J Urol 1966; 95: 771-775.
6. Conley JE et al. "Aortic obstruction associated with methysergide maleate therapy for headaches" JAMA 1966; 198 (8): 136-138.
7. Stecker JF et al. "Retroperitoneal fibrosis and ergot derivatives" J Urol 1974; 112:.30-32.
8. Malaquin F et al. "Pleural and retroperitoneal fibrosis from dihydroergotamine" N Engl J Med 1989; 321 (25): 1760.
9. Damstrup L and Jensen TT "Retroperitoneal fibrosis after long-term daily use of ergotamine" Int Urol Nephrol 1986; 18 (3): 299-301.
10. Molto Ripoll F et al. "Fibrosis retroperitoneal por ergotamina. A proposito de un caso" Arch Esp Urol 1995; 48 (4): 400-403.
11. Lepage-Savary D and Vallières A "Ergotamine as a possible cause of retroperitoneal fibrosis" Clin Pharm 1982; 1: 179-180.
12. Tournigand P et al. "Une cause rare de compression veineuse intra-abdominale. La fibrose rétropéritonéale (à propos d'un cas)" Phlébologie 1974; 27 (2): 161-165.
13. Correas Gomez M et al. "Fibrose rétropéritonéale chez un patient traité par bromocriptine pour prolactinome" J Urol 1991; 97 (4-5): 234-236.
14. Vermersch P et al. "Fibrose rétropéritonéale après traitement par la bromocriptine" Presse Med 1989; 18 (16): 841.
15. Herzog A et al. "Retroperitoneal fibrosis in a patient with macroprolactinoma treated with bromocriptine" BMJ 1989; 298: 1315.
16. Hardy JC et al. "Fibrose rétropéritonéale. À propos de trois cas dont deux induits par la bromocriptine" Acta Urologica Belgica 1991; 59 (3): 95 -103.
17. Kaminsky P et al. "Fibrose rétropéritonéale après traitement par la bromocriptine" Presse Med 1989; 18 (15): 777.
18. Bowler JV et al. "Retroperitoneal fibrosis and bromocriptine" Lancet 1986; 2: 466.
19. Murphy F and Pickard RS "Bromocriptine-associated retroperitoneal fibrosis presenting with testicular retraction" Br J Urol 1989; 64 (3): 318-319.
20. Ward CD et al. "Pleuropulmonary and retroperitoneal fibrosis associated with bromocriptine treatment" J Neurol Neurosurg Psychiatry 1987; 50 (12): 1706-1707.
21. Hely MA et al. "Retroperitoneal fibrosis, skin and pleuropulmonary changes associated with bromocriptine therapy" Austr NZ J Med 1991; 21: 82-84.
22. Mondal BK and Suri S "Pergolide-induced retroperitoneal fibrosis" Int J Clin Pract 2000; 54 (6): 403.
23. Kunkler RB et al. "Retroperitoneal fibrosis caused by treatment with pergolide in a patient with Parkinson's disease" Br J Urol 1998; 82: 147.
24. Lund BC et al. "Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis" Pharmacotherapy 1999; 19 (12): 1437-1438.
25. Shaunak S et al. "Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide" J Neurol Neurosury Psychiatry 1999; 66: 79-81.
26. Campieri C et al. "Dihydroergocristine-induced retroperitoneal fibrosis with an episode of reversible obstructive acute renal failure" Nephron 1995; 69: 184-185.
27. Rinne UK "Pleuropulmonary changes during long term bromocriptine treatment for Parkinson's disease" Lancet 1981; 1: 44.
28. Tornling G et al. "Pleuropulmonary reactions in patients on bromocriptine treatment" Eur J Respir Dis 1986; 68: 35-38.
29. McElvaney NG et al. "Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease" Arch Intern Med 1988; 148: 2231-2236.
30. Saura J et al. "Derrame pleural y pericarditis constrictiva secundarios al tratamiento con bromocriptina" Neurologia 1991; 6 (9 : 331-333.
31. Danoff SK et al. "Pleuropulmonary disease due to pergolide use in restless legs syndrome" Chest 2001; 120 (1): 313-316.
32. Bhatt MH et al. "Pleuropulmonary disease associated with dopamine agonist therapy" Ann Neurol 1991; 30 (4): 613-616.
33. Frans E et al. "Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline" Eur Resp J 1992; 5: 263-265.
34. Ling LH et al. "Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease" Mayo Clin Proc 1999; 74: 371-375.
35. Oechsner M et al. "Pleural fibrosis associated with dihydroergocryptine treatment" Acta Neurol Scand 2000; 101: 283-285.
36. Foucher P et al. "Accidents respiratoires médica-menteux. Étude de 27 observations" Thérapie 1989; 44: 229-235.
37. Pfitzenmeyer P et al. "Pleuropulmonary changes induced by ergoline drugs" Eur Resp J 1996; 9: 1013-1019.
38. Orlando RC et al. "Methysergide therapy and constrictive pericarditis" Ann Intern Med 1978; 88 (2): 213-214.
39. Champagne S et al. "Chronic constrictive pericarditis induced by long-term bromocriptine therapy: report or two cases" Ann Pharmacother 1999; 33: 1050-1054.
40. Graham JR "Cardiac and pulmonary fibrosis during methysergide therapy for headache" Am J Med Sci 1967; 254: 23-34.
41. Bana DS et al. "Cardiac murmurs and endocardial fibrosis associated with methysergide therapy" Am Heart J 1974; 88 (5): 640-655.
42. Mason JW et al. "Methysergide-induced heart disease: a case of multivalvular and myocardial fibrosis" Circulation 1977; 56 (5): 889-890.
43. Misch KA "Development of heart valve lesions during methysergide therapy" BMJ 1974; 2: 365-366.
44. Slugg PH and Kunkel RS "Complications of methysergide therapy - retroperitoneal fibrosis, mitral regurgitation, edema and hemolytic anemia" JAMA 1970; 213 (2): 297-298.
45. "Methysergide and cardiac valvulopathy" Australian Adverse Drug Reactions Bulletin 2000; 19 (4): 15.
46. Munroe DS et al. "Mitral regurgitation occurring during methysergide (Sansert) therapy" Can Med Assoc J 1969; 101: 536-539.
47. Barrillon A et al. "Fibrose rétro-péritonéale. À propos d'un cas induit par méthysergide compliqué d'artériopathie fémorale et d'insuffisance tricuspide" Nouv Presse Med 1974; 3 (7): 377-379.
48. Redfield MM et al. "Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations" Ann Intern Med 1992; 117 (1): 50-52.
49. Spierings ELH "Cardiac murmurs indicative of aortic valve disease with chronic and excessive intake of ergotamine" Headache 1988; 28: 278-279.
50. Hauck AJ et al. "Mitral and aortic valve disease associated with ergotamine therapy for migraine - report of two cases and review of literature" Arch Pathol Lab Med 1990; 114: 62-64.
51. Hendrikx M et al. "Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature" J Heart Valve Dis 1996; 5 (2): 235-237.
52. Austin SM et al. "Mitral valve disease associated with long-term ergotamine use" South Med J 1993; 86 (10): 1179-1181.
53. Wilke A et al. "Mitral, aortic and tricuspid valvular heart disease associated with ergotamine therapy for migraine" Eur Heart J 1997; 18: 701.
54. Flaherty KR and Bates JR "Mitral regurgitation caused by chronic ergotamine use" Am Heart J 1996; 131 (3): 603-606.
55. "Mirapex° - pramipexole". In: "Physicians' Desk Reference" Medical Economics Company, Montvale 2002: 2834-2838.
56. "Fibrotic reactions with pergolide and other ergot-deritatives dopamine receptor agonists" Current Problems in Pharmacovigilance 2002; 28: 3.
57. Balachandran KP et al. "Chronic pericardial constriction linked to the antiparkinsonian dopamine agonist pergolide" Postgrad Med J 2002; 78: 49-50.
58. Prescrire Editorial Staff "Severe heart valve disease on appetite suppressants" Prescr Int 1998; 7 (33): 19-20.
59. Dahl CF and Allen MR "Regression and progression of valvulopathy associated with fenfluramine and phentermine" Ann Intern Med 2001; 136 (6): 489.